Articles tagged with Cardiac Pacemakers
The new consensus statement provides updated guidance on CIED lead management, including extraction and management of traditional devices and newer technologies. The recommendations aim to reduce clinical challenges and morbidity within a rapidly evolving technological landscape, ensuring better quality of life for patients.
This prospective cohort study evaluated the two-year safety outcomes of cardiac pacemakers, implantable cardioverter-defibrillators, and cardiac resynchronization therapy devices in a tertiary care setting. The study found no significant disparities between males and females across various variables.
A new smartphone app, ECHAS, can help people determine if they are suffering from a heart attack or stroke and need medical attention. The app, developed by experts at UVA Health and other leading institutions, proved effective in identifying patients with cardiac and neurological emergencies.
A study published in Heart Rhythm has found that handheld electro-shockers can interact with cardiac implantable electronic devices (CIEDs) such as pacemakers, posing a risk to individuals. The risk is primarily based on the applied voltage, but also on the manufacturer and type of implanted CIED.
Northwestern University engineers developed the world's smallest pacemaker that can be non-invasively injected into newborn babies' hearts with a syringe. The device, paired with a wearable wireless controller, stimulates pacing through light pulses, dissolving after use without surgical extraction.
A 13-year-old patient underwent a minimally invasive procedure to receive a dual chamber leadless pacemaker, treating congenital complete heart block. The AVEIR device was implanted via the right internal jugular vein, allowing the child to resume sports activities without restrictions.
A University of Michigan-led study suggests that recycled pacemakers can be used safely and effectively in patients with life-threatening cardiac conditions. The international clinical trial involved nearly 300 people across seven countries and found no significant differences in pacemaker function up to 90 days after the procedure.
A randomized trial found reconditioned pacemakers comparable to new devices in terms of safety and effectiveness up to 90 days after implantation. However, longer-term follow-up is necessary to confirm the safety and efficacy of reconditioned devices.
A temporary heart stimulator self-assembles around the heart after injecting nanoparticles, correcting irregular heartbeats and facilitating ECG measurements. The device can operate for up to five days with low power inputs from handheld devices like mobile phones.